Bavarian Nordic gets U.S. contract; Price of Novartis' Bexsero could be problematic;

> Los Angeles health officials and charities are offering free meningitis vaccines after a man died of the disease last week. News

> Bavarian Nordic has secured a $228 million supply deal with the U.S. for the smallpox vaccine that accounts for the bulk of its sales. Article

> Research suggests T cells play a protective role in the immune response against dengue fever and should be factored into vaccine design. Study

> Medicago has reported that its H5N1 vaccine was well tolerated in a Phase I trial. Release

> Research firm GlobalData has warned that cost-effectiveness concerns may stop governments from adding Novartis' ($NVS) Bexsero to vaccination programs. Item

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.